Mani Foroohar
Stock Analyst at Leerink Partners
(2.35)
# 2,737
Out of 5,008 analysts
171
Total ratings
48.94%
Success rate
-2.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $8.36 | +139.23% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.53 | +98.30% | 13 | Oct 3, 2025 | |
| MRNA Moderna | Maintains: Underperform | $18 → $15 | $28.35 | -47.09% | 18 | Aug 22, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $23.33 | -57.14% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $6.29 | -4.61% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $9.54 | +183.02% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $26.21 | +174.70% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $3.38 | +402.96% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $73.78 | -33.59% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $54.85 | -16.13% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $7.36 | +198.91% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $70.74 | -12.36% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $14.36 | -9.47% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $21.03 | +37.90% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.43 | -26.34% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $11.92 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $7.26 | +327.00% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.85 | +279.40% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $36.66 | +9.11% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $26.38 | +218.42% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $4.26 | +64.32% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $27.45 | +180.51% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $458.77 | -68.83% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.56 | +7.91% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $77.97 | -2.53% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.73 | +1,145.42% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.79 | +317.54% | 6 | Jul 23, 2021 |
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $8.36
Upside: +139.23%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.53
Upside: +98.30%
Moderna
Aug 22, 2025
Maintains: Underperform
Price Target: $18 → $15
Current: $28.35
Upside: -47.09%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $23.33
Upside: -57.14%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $6.29
Upside: -4.61%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $9.54
Upside: +183.02%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $26.21
Upside: +174.70%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $3.38
Upside: +402.96%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $73.78
Upside: -33.59%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $54.85
Upside: -16.13%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $7.36
Upside: +198.91%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $70.74
Upside: -12.36%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $14.36
Upside: -9.47%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $21.03
Upside: +37.90%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.43
Upside: -26.34%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $11.92
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $7.26
Upside: +327.00%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.85
Upside: +279.40%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $36.66
Upside: +9.11%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $26.38
Upside: +218.42%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $4.26
Upside: +64.32%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $27.45
Upside: +180.51%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $458.77
Upside: -68.83%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.56
Upside: +7.91%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $77.97
Upside: -2.53%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.73
Upside: +1,145.42%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.79
Upside: +317.54%